These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 20142119

  • 1. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.
    Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, Brissy O, Lambert M, Morange PE, Alessi MC, Bonnet JL.
    Arch Cardiovasc Dis; 2010 Jan; 103(1):39-45. PubMed ID: 20142119
    [Abstract] [Full Text] [Related]

  • 2. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [Abstract] [Full Text] [Related]

  • 3. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    J Thromb Haemost; 2010 Jan; 8(1):37-42. PubMed ID: 19818001
    [Abstract] [Full Text] [Related]

  • 4. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, Bali L, Morange PE, Alessi MC, Bonnet JL.
    Am J Cardiol; 2009 Oct 15; 104(8):1078-82. PubMed ID: 19801028
    [Abstract] [Full Text] [Related]

  • 5. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
    Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D.
    J Thromb Haemost; 2010 Mar 15; 8(3):482-8. PubMed ID: 20040042
    [Abstract] [Full Text] [Related]

  • 6. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
    El Ghannudi S, Ohlmann P, Meyer N, Wiesel ML, Radulescu B, Chauvin M, Bareiss P, Gachet C, Morel O.
    JACC Cardiovasc Interv; 2010 Jun 15; 3(6):648-56. PubMed ID: 20630458
    [Abstract] [Full Text] [Related]

  • 7. Platelet function analysis: at the edge of meaning.
    Oestreich JH, Smyth SS, Campbell CL.
    Thromb Haemost; 2009 Feb 15; 101(2):217-9. PubMed ID: 19190799
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Haemost; 2009 Feb 15; 101(2):333-9. PubMed ID: 19190818
    [Abstract] [Full Text] [Related]

  • 9. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
    Freynhofer MK, Brozovic I, Bruno V, Farhan S, Vogel B, Jakl G, Willheim M, Hübl W, Wojta J, Huber K.
    Thromb Haemost; 2011 Aug 15; 106(2):230-9. PubMed ID: 21614416
    [Abstract] [Full Text] [Related]

  • 10. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D, Magyarlaki T, Tokés-Füzesi M, Rideg O, Vorobcsuk A, Komócsi A.
    Platelets; 2010 Aug 15; 21(7):563-70. PubMed ID: 20642320
    [Abstract] [Full Text] [Related]

  • 11. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C, Berge N, Boval B, Dubar M, Drouet L.
    Thromb Haemost; 2010 Sep 15; 104(3):571-81. PubMed ID: 20664906
    [Abstract] [Full Text] [Related]

  • 12. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
    Cuisset T, Hamilos M, Delrue M, Frère C, Verhamme K, Bartunek J, Saut N, Bonnet JL, Eijgelsheim M, Wijns W, Alessi MC, Barbato E.
    Thromb Haemost; 2010 Apr 15; 103(4):774-9. PubMed ID: 20135061
    [Abstract] [Full Text] [Related]

  • 13. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G.
    Am J Cardiol; 2011 Apr 01; 107(7):995-1000. PubMed ID: 21256470
    [Abstract] [Full Text] [Related]

  • 14. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C, Ayral Y, Morguet A, Schultheiss HP, Rauch U.
    Cardiovasc Revasc Med; 2012 Apr 01; 13(3):159-66. PubMed ID: 22503564
    [Abstract] [Full Text] [Related]

  • 15. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?
    Cotton JM, Worrall AM, Hobson AR, Smallwood A, Amoah V, Dunmore S, Nevill AM, Raghuraman RP, Vickers J, Curzen N.
    Cardiovasc Ther; 2010 Jun 01; 28(3):139-46. PubMed ID: 20406238
    [Abstract] [Full Text] [Related]

  • 16. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
    Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, Cazenave JP, Dickele MC, Monassier JP, Gachet C.
    JACC Cardiovasc Interv; 2008 Dec 01; 1(6):631-8. PubMed ID: 19463377
    [Abstract] [Full Text] [Related]

  • 17. Post-thienopyridine platelet response, cardiovascular outcomes, and personalized therapy: En attendant Godot.
    Tsimikas S, Leibundgut G.
    JACC Cardiovasc Interv; 2010 Jun 01; 3(6):657-9. PubMed ID: 20630459
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.
    Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, Giusti B, Balzi D, Prisco D, Abbate R.
    Thromb Haemost; 2010 Aug 01; 104(2):287-92. PubMed ID: 20458439
    [Abstract] [Full Text] [Related]

  • 19. Does hemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test?
    Geara AS, Ayoub I, Abi Rached J, Siddique MN, Ghimire P, El-Sayegh S.
    Am J Cardiol; 2011 Apr 01; 107(7):1103-4. PubMed ID: 21419895
    [No Abstract] [Full Text] [Related]

  • 20. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H, Lask S, Engelhardt A, Mügge A.
    Thromb Haemost; 2008 Feb 01; 99(2):357-62. PubMed ID: 18278186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.